Published in Mod Pathol on August 28, 2009
Noninvasive genomic detection of melanoma. Br J Dermatol (2011) 2.17
Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. J Mol Diagn (2011) 1.53
Analysis of the genome to personalize therapy for melanoma. Oncogene (2010) 1.33
Mucosal melanomas: a case-based review of the literature. Oncologist (2010) 1.20
A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther (2015) 1.19
Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol (2010) 1.13
Delving into somatic variation in sporadic melanoma. Pigment Cell Melanoma Res (2012) 0.99
Diagnostic criteria, specific mutations, and genetic predisposition in gastrointestinal stromal tumors. Appl Clin Genet (2010) 0.91
Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma. Dermatol Res Pract (2011) 0.91
NUAK2: an emerging acral melanoma oncogene. Oncotarget (2011) 0.90
Treating advanced melanoma: current insights and opportunities. Cancer Manag Res (2014) 0.89
Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations. Hum Pathol (2013) 0.89
Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Br J Cancer (2011) 0.88
Additional Primary Malignancies in Patients with Gastrointestinal Stromal Tumor (GIST): A Clinicopathologic Study of 260 Patients with Molecular Analysis and Review of the Literature. Ann Surg Oncol (2015) 0.88
The current state of targeted therapy in melanoma: this time it's personal. Semin Oncol (2012) 0.86
[Hereditary and non-hereditary syndromic gastointestinal stromal tumours]. Pathologe (2010) 0.83
The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions. Eur J Histochem (2011) 0.83
Cell proliferation in cutaneous malignant melanoma: relationship with neoplastic progression. ISRN Dermatol (2012) 0.81
Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract. J Am Acad Dermatol (2014) 0.81
Molecular alterations in malignant blue nevi and related blue lesions. Virchows Arch (2015) 0.79
Expression of Sox10 and c-kit in sinonasal mucosal melanomas arising in the Chinese population. Head Neck Pathol (2012) 0.79
Concordance of c-kit mutational status in matched primary and metastatic cutaneous canine mast cell tumors at baseline. J Vet Intern Med (2013) 0.77
Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). Oncologist (2015) 0.75
Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Mucosal Melanomas. Head Neck Pathol (2017) 0.75
Comparison of c-Kit expression between primary and metastatic melanoma of skin and mucosa. Med J Islam Repub Iran (2015) 0.75
Anorectal melanoma with a KIT-activating mutation, which is a target for tyrosine kinase inhibitor. Int J Clin Oncol (2010) 0.75
A Review of the Aetiopathogenesis and Clinical and Histopathological Features of Oral Mucosal Melanoma. ScientificWorldJournal (2017) 0.75
Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America. Clin Transl Oncol (2017) 0.75
Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol (2006) 7.76
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res (2005) 5.44
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer (2006) 4.92
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology (2005) 3.90
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res (2004) 3.63
Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol (2002) 3.29
Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol (2008) 3.16
Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther (2002) 2.68
KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res (2008) 2.57
Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res (1998) 2.44
Prevalence of KIT expression in human tumors. J Clin Oncol (2004) 2.40
Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol (1999) 2.36
Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol (2006) 2.25
Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol (2005) 2.16
Activating c-kit gene mutations in human germ cell tumors. Am J Pathol (1999) 2.15
The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol (1998) 2.08
Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res (2008) 1.98
Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res (2007) 1.94
L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer (2007) 1.76
Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer (2006) 1.75
Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res (2008) 1.73
Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer (2005) 1.66
Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO J (1998) 1.56
c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas. Mol Biol Cell (1992) 1.50
Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer (2008) 1.43
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res (2008) 1.39
Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer (1992) 1.34
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res (2008) 1.33
KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells. Oncogene (1993) 1.30
C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch (2007) 1.26
Loss of c-kit expression in cultured melanoma cells. Oncogene (1992) 1.26
Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol (1997) 1.23
Melanin binds reversibly to thermostable DNA polymerase and inhibits its activity. Biochem Biophys Res Commun (2000) 1.22
Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol (2008) 1.20
Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors. Clin Cancer Res (2005) 1.19
Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol (2008) 1.14
Anorectal malignant melanoma: morphologic and immunohistochemical features. Am J Clin Pathol (2006) 1.10
Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis. J Biol Chem (2004) 1.08
Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J Cutan Pathol (2003) 1.03
Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec). J Cutan Pathol (2006) 0.97
Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. Clin Cancer Res (2009) 0.95
Bovine serum albumin reverses inhibition of RT-PCR by melanin. Biotechniques (1998) 0.95
Kit and melanocyte migration. J Invest Dermatol (2006) 0.94
Primary melanoma of the skin and cutaneous melanomatous metastases: comparative histologic features and immunophenotypes. Am J Clin Pathol (2004) 0.93
C-kit Asp-816-Val mutation analysis in patients with mastocytosis. Dermatology (2007) 0.92
In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation. Blood Cells Mol Dis (1998) 0.91
An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients. Melanoma Res (2005) 0.90
Immunohistochemical determination of HER-2/neu overexpression in malignant melanoma reveals no prognostic value, while c-Kit (CD117) overexpression exhibits potential therapeutic implications. J Carcinog (2003) 0.89
Unlucky number 13? Differential effects of KIT exon 13 mutation in gastrointestinal stromal tumors. Mol Oncol (2008) 0.87
Malignant blue nevus with lymph node metastases. J Cutan Pathol (2007) 0.85
Characterization of tyrosine kinase I domain c-kit gene mutation Asn655Lys newly found in primary jejunal gastrointestinal stromal tumor. Am J Gastroenterol (2007) 0.82
Tyrosine kinase activating mutations in human malignancies: implications for diagnostic pathology. Exp Mol Pathol (2008) 0.80
Potential use of imatinib mesylate in ocular melanoma and liposarcoma expressing immunohistochemical c-KIT (CD117). Ann Oncol (2003) 0.77
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
NT5E mutations and arterial calcifications. N Engl J Med (2011) 8.71
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med (2014) 4.70
Shaping cities for health: complexity and the planning of urban environments in the 21st century. Lancet (2012) 4.51
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res (2004) 3.63
Public health benefits of strategies to reduce greenhouse-gas emissions: overview and implications for policy makers. Lancet (2009) 3.51
Leukemia cutis. Am J Clin Pathol (2008) 3.38
Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ (2007) 3.30
Preliminary report on the International Conference for the Development of Standards for the Treatment of Anorectal Malformations. J Pediatr Surg (2005) 3.17
Public health benefits of strategies to reduce greenhouse-gas emissions: household energy. Lancet (2009) 3.03
Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST). Proc Natl Acad Sci U S A (2010) 3.00
Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol (2007) 2.72
NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer (2011) 2.69
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant (2006) 2.63
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
The reno-vascular A2B adenosine receptor protects the kidney from ischemia. PLoS Med (2008) 2.43
Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci U S A (2007) 2.38
Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol (2002) 2.35
Deletion of Cavin/PTRF causes global loss of caveolae, dyslipidemia, and glucose intolerance. Cell Metab (2008) 2.28
Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience. J Urol (2005) 2.25
Prognostic factors for survival in melanoma patients with brain metastases. Cancer (2010) 2.23
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res (2009) 2.21
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol (2012) 2.21
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer (2009) 2.20
EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer Cytopathol (2011) 2.19
Use of p63 expression in distinguishing primary and metastatic cutaneous adnexal neoplasms from metastatic adenocarcinoma to skin. J Cutan Pathol (2007) 2.14
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol (2013) 2.13
The skin allograft revisited: a potentially permanent wound coverage option in the critically ill patient. Plast Reconstr Surg (2009) 2.13
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol (2013) 2.13
Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res (2010) 2.11
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
The performance of MelaFind: a prospective multicenter study. Arch Dermatol (2010) 2.07
Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg (2009) 2.04
Angiosarcoma of the breast. Cancer (2005) 1.98
Cutaneous carcinosarcoma: further insights into its mutational landscape through massive parallel genome sequencing. Virchows Arch (2014) 1.93
Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK. Am J Surg Pathol (2011) 1.91
Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest (2008) 1.87
Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One (2010) 1.87
Pd(II)-catalyzed enantioselective oxidative tandem cyclization reactions. Synthesis of indolines through C-N and C-C bond formation. J Am Chem Soc (2006) 1.86
Complicated diverticulitis: is it time to rethink the rules? Ann Surg (2005) 1.82
Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. Mod Pathol (2012) 1.80
Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med (2011) 1.79
Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res (2010) 1.78
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer (2004) 1.78
Mortality risk from squamous cell skin cancer. J Clin Oncol (2005) 1.74
Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol (2010) 1.71
State of the art, nomenclature, and points of consensus and controversy concerning benign melanocytic lesions: outcome of an international workshop. Adv Anat Pathol (2010) 1.68
Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol (2008) 1.67
Locoregional disease patterns in well-differentiated and dedifferentiated retroperitoneal liposarcoma: implications for the extent of resection? Ann Surg Oncol (2014) 1.67
Ewing's sarcoma: standard and experimental treatment options. Curr Treat Options Oncol (2009) 1.66
Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol (2002) 1.65
Usefulness of serum tryptase level as an independent biomarker for coronary plaque instability in a Chinese population. Atherosclerosis (2011) 1.64
Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol (2003) 1.64
Upregulation of Nox4 in the aging vasculature and its association with smooth muscle cell polyploidy. Cell Cycle (2009) 1.63
Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial. Ann Intern Med (2010) 1.62
Cutaneous adnexal tumor with an unusual presentation--discussion of a potential diagnostic pitfall. Am J Dermatopathol (2009) 1.62
HMB-45 (gp103) and MART-1 expression within giant cells in an atypical fibroxanthoma: a case report. J Cutan Pathol (2004) 1.62
Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn (2012) 1.59
Home energy efficiency and radon related risk of lung cancer: modelling study. BMJ (2014) 1.58
Cutaneous leiomyosarcoma originating in a symplastic pilar leiomyoma: a rare occurrence and potential diagnostic pitfall. J Cutan Pathol (2011) 1.55
Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res (2012) 1.55
Primary angiosarcomas of the breast. Cancer (2007) 1.54
Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer (2006) 1.54
Expression of HMGB1 and RAGE in rat and human brains after traumatic brain injury. J Trauma Acute Care Surg (2012) 1.53
CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell (2013) 1.53
Conjunctival squamous cell carcinoma in the anophthalmic socket. Ophthal Plast Reconstr Surg (2008) 1.53
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther (2009) 1.53
SIRT4 coordinates the balance between lipid synthesis and catabolism by repressing malonyl CoA decarboxylase. Mol Cell (2013) 1.52
Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer (2011) 1.50
Comparison of primary and metastatic malignant melanoma of the esophagus: clinicopathologic review of 10 cases. Arch Pathol Lab Med (2008) 1.50
A2B adenosine receptor gene deletion attenuates murine colitis. Gastroenterology (2008) 1.49
A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J Clin Oncol (2013) 1.47
Pd(II)/(t)Bu-quinolineoxazoline: an air-stable and modular chiral catalyst system for enantioselective oxidative cascade cyclization. Org Lett (2009) 1.47
Small-intestinal rhabdoid gastrointestinal stromal tumor (GIST): mutation analysis and clinical implications of a rare morphological variant. Int J Surg Pathol (2011) 1.45
Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid (2013) 1.45
Reduction of adhesions with composite AlloDerm/polypropylene mesh implants for abdominal wall reconstruction. Plast Reconstr Surg (2004) 1.45
Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg (2003) 1.45
HER-2/neu expression in extramammary Paget disease: a clinicopathologic and immunohistochemistry study of 47 cases with and without underlying malignancy. J Cutan Pathol (2009) 1.44
Trisomy 14 as a sole chromosome abnormality is associated with older age, a heterogenous group of myeloid neoplasms with dysplasia, and a wide spectrum of disease progression. J Biomed Biotechnol (2011) 1.43
Primary vascular tumors and tumor-like lesions of the kidney: a clinicopathologic analysis of 25 cases. Am J Surg Pathol (2010) 1.41
NF-kappaB is required for UV-induced JNK activation via induction of PKCdelta. Mol Cell (2006) 1.41
Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist (2013) 1.41
Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. PLoS One (2009) 1.40